Publication Date:
2006-11-16
Description:
Background: RBC transfusions remain a mainstay in the treatment in MDS, but their characteristics in a large MDS population have not been reported in detail. Indications of iron chelation therapy (CT) in those patients, are based on consensus (Gattermann Hematology/Oncology Clinics 2005;19:supp1 ) but have not been reported in a large MDS cohort. In addition, a positive effect of desferioxamine (DFO) therapy on hematopoiesis has been reported in a small group of MDS (Jensen BJH, 1996;94:288). Methods: We analyzed the hematological characteristics, RBC transfusion requirement and iron CT in MDS patients referred for RBC transfusion in 18 French centers between May 15 and June 15, 2005. Results: 170 pts were included in the survey, median age 75 (14–95); M/F ratio 1.37; median time from diagnosis was 43 months (1 month to 17.5 years); WHO: pure RA 8.8%, pure RARS 18%, RCMD 3.5%, RCMD-RS 3%, RAEB I 16.5%, RAEB II 5.3%, 5q- syndrome 7%, CMML 4.7%, unclassified12.6%. Karyotype: fav (12%), int (37%), unfav ( 23%), failure or not done ( 28%). IPSS: low 39%, Int1 45%, Int2 13.5%, high 2.5%, unavailable 28%. Median serum ferritin (SF) level at diagnosis was 562ng/ml (9–2500). Median number of RBC units transfused since diagnosis was 49, mean 80 (2–610) and did not differ statistically according to WHO or IPSS. 81% of patients had received 〉 21 RBC units. Median number of RBC units transfused at initiation of CT was 21 (2–151). 68/170 pts ( 40 %) had received CT during the disease course including: DFO continuous s/c (8h) (40mg/kg/d, 3 to 5d/ week) n = 37, DFO s/c bolus (2 to 8g/week) n = 14, DFO IV (50 to 100mg/kg/d once after each RBC transfusion) n=7, deferiprone alone (30 to 75 mg/kg/d) n=4. Deferiprone + DFO s/c n=6. Median SF level was 1492ng/ml at the start of iron CT (436–6572). 50/68 pts were still on iron CT at the time of the survey after 2 to 114 months. Median SF level at the time of survey was 1828ng/ml (not statistically different from pre CT level). No positive effects were observed on hematopoiesis even in pts chelated for prolonged periods. 18/68 patients stopped CT (all were on DFO therapy) due to over efficacy n= 1, local complications n = 7, patient decision n=10 ). Median duration of treatment was 9 months (1–78) and median level of SF 3227ng/ml at the time of survey in those 18pts. For the 102/170 pts who did not receive CT, main reasons given by physicians were: older age 33% (median age in this group was indeed 82); cumbersome treatment 12%; high IPSS 8% (all cases had indeed IPSS〉=1.5); low transfusion requirement 8% (median=11 RBC units transfused in this group); other reasons 5% (refusal, skin lesions), no reason given 34%. By comparison to non chelated patients, chelated patients had significantly higher number of RBC units transfused (mean 115 vs 55) (p
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink